- Home
- HEPA vs ONCO Comparison
HEPA vs ONCO Comparison
Compare HEPA & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HEPA
- ONCO
- Stock Information
- Founded
- HEPA 2013
- ONCO 2018
- Country
- HEPA United States
- ONCO United States
- Employees
- HEPA N/A
- ONCO N/A
- Industry
- HEPA Biotechnology: Pharmaceutical Preparations
- ONCO Biotechnology: Pharmaceutical Preparations
- Sector
- HEPA Health Care
- ONCO Health Care
- Exchange
- HEPA Nasdaq
- ONCO Nasdaq
- Market Cap
- HEPA 4.1M
- ONCO 3.3M
- IPO Year
- HEPA N/A
- ONCO 2022
- Fundamental
- Price
- HEPA $0.57
- ONCO $0.40
- Analyst Decision
- HEPA Hold
- ONCO
- Analyst Count
- HEPA 1
- ONCO 0
- Target Price
- HEPA N/A
- ONCO N/A
- AVG Volume (30 Days)
- HEPA 27.6K
- ONCO 282.9K
- Earning Date
- HEPA 11-14-2024
- ONCO 12-24-2024
- Dividend Yield
- HEPA N/A
- ONCO N/A
- EPS Growth
- HEPA N/A
- ONCO N/A
- EPS
- HEPA N/A
- ONCO N/A
- Revenue
- HEPA N/A
- ONCO $1,870,605.00
- Revenue This Year
- HEPA N/A
- ONCO N/A
- Revenue Next Year
- HEPA N/A
- ONCO N/A
- P/E Ratio
- HEPA N/A
- ONCO N/A
- Revenue Growth
- HEPA N/A
- ONCO N/A
- 52 Week Low
- HEPA $0.48
- ONCO $0.37
- 52 Week High
- HEPA $3.72
- ONCO $21.40
- Technical
- Relative Strength Index (RSI)
- HEPA 39.66
- ONCO 22.61
- Support Level
- HEPA $0.48
- ONCO $0.37
- Resistance Level
- HEPA $0.66
- ONCO $0.47
- Average True Range (ATR)
- HEPA 0.06
- ONCO 0.10
- MACD
- HEPA -0.01
- ONCO 0.10
- Stochastic Oscillator
- HEPA 32.88
- ONCO 15.28
About HEPA Hepion Pharmaceuticals Inc.
Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan-cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.
About ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.